시장보고서
상품코드
1786929

세계의 위암 진단 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 제품 유형별, 질환 유형별, 최종 용도별, 지역별 예측(2025-2034년)

Gastric Cancer Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type, By End Use, By Region - Market Forecast, 2025-2034

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 125 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 세계의 위암 진단 시장 규모는 2034년까지 27억 8,000만 달러에 이를 전망입니다. 이 조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

위암 진단 시장은 위암의 검출과 확인에 사용되는 다양한 방법과 기술에 초점을 맞추었습니다. 여기에는 의료 전문가가 질병의 조기 발견, 확산 판정, 적절한 치료 계획을 수립하는 데 사용하는 다양한 의학적 검사, 치료 및 평가가 포함됩니다. 이러한 진단 접근법은 이미지 검사, 내시경 검사, 조직 생검, 혈액 검사, 고급 분자 분석 등을 포함하며, 모두 정확하고 시기 적절한 진단을 제공하는 것을 목표로 합니다.

위암 진단 시장의 성장은 세계 위암 증례 수가 증가하고 있기 때문에 당연히 진단 서비스에 대한 수요도 높아지고 있습니다. 또한 암을 조기에 발견함으로써 치료가 성공하는 경우가 많기 때문에 검진 프로그램에 의한 조기 발견이 중시되도록 되어 있습니다. 이 업계는 또한 현재 진행 중인 기술적 진보로부터 혜택을 누리고 있으며, 보다 새롭고, 정확하고, 침습성이 낮은 진단 도구를 이용할 수 있게 되어, 보다 효과적으로 질병을 확인하고, 개별 환자에 맞는 치료를 하는 데 도움이 됩니다.

위암 진단 시장 보고서 하이라이트

제품별로는 루틴의 혈액 검사부터 고도의 분자 분석에 이르기까지, 거의 모든 진단 검사에 시약 및 소모품이 필수적이기 때문에 시약 및 소모품 부문이 2024년에 최대 점유율을 차지했습니다.

질병 유형별로는 위암의 가장 일반적인 형태로 압도적인 보급률을 자랑하는 선암이 2024년에 최대 점유율을 차지했습니다. 진단 노력과 자원 배분의 대부분은 당연히 이 광범위한 병형의 확인과 특성화를 향하고 있습니다.

최종 사용자별로는 병원 부문이 2024년 가장 큰 점유율을 차지했습니다. 병원은 환자가 일반적으로 초기 진단을 받고, 내시경 치료를 받고, 종합적인 진단 인프라를 이용하는 주요 의료시설이기 때문입니다.

북미의 위암 진단 시장이 2024년에 가장 큰 점유율을 차지한 것은 고급 의료 인프라, 조기 진단에 대한 높은 의식, 정밀의료에 대한 강한 관심 때문입니다. 아시아태평양 시장은 특히 동아시아 국가에서 높은 위암 이환율에 견인되어 급속히 확대되고 있습니다.

이 시장의 주요 기업으로는 F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Illumina, Inc., Myriad Genetics, Inc., Mirxes Pte.Ltd., Vela Diagnostics, BIOMERIEUX, AI Medical Service Inc. 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 위암 진단 시장 인사이트

  • 시장 현황
  • 위암 진단 시장 역학
    • 성장 촉진요인과 기회
      • 위암의 세계적 발생률 상승
      • 진단 기술의 진보
    • 억제요인과 과제
      • 한정된 조기 발견 방법
  • PESTEL 분석
  • 위암 진단 시장의 응용 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 위암 진단 시장 : 제품별

  • 주요 조사 결과
  • 소개
  • 시약 및 소모품
  • 기기

제6장 세계의 위암 진단 시장 : 질환 유형별

  • 주요 조사 결과
  • 소개
  • 선암
  • 위 림프종
  • 기타

제7장 세계의 위암 진단 시장 : 최종 용도별

  • 주요 조사 결과
  • 소개
  • 병원
  • 진단 실험실
  • 진단 이미지

제8장 세계의 위암 진단 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 위암 진단 시장 분석 : 지역별, 2020-2034년
  • 북미
    • 북미 : 제품별, 2020-2034년
    • 북미 : 질환별, 2020-2034년
    • 북미 : 최종 용도별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 제품별, 2020-2034년
    • 유럽 : 질환별, 2020-2034년
    • 유럽 : 최종 용도별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 제품별, 2020-2034년
    • 아시아태평양 : 질병 유형별, 2020-2034년
    • 아시아태평양 : 최종 용도별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 제품별, 2020-2034년
    • 중동 및 아프리카 : 질병 유형별, 2020-2034년
    • 중동 및 아프리카 : 최종 용도별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 제품별, 2020-2034년
    • 라틴아메리카 : 질병 유형별, 2020-2034년
    • 라틴아메리카 : 최종 용도별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확대 및 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 프로파일

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AI Medical Service Inc.
  • BIOMERIEUX
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Mirxes Pte. Ltd.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Vela Diagnostics
JHS 25.08.18

The global gastric cancer diagnostics market size is expected to reach USD 2.78 billion by 2034, according to a new study by Polaris Market Research. The report "Gastric Cancer Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type, By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The gastric cancer diagnostics market focuses on the various methods and technologies used to detect and confirm stomach cancer. This involves a range of medical tests, procedures, and evaluations that healthcare professionals use to identify the disease in its early stages, determine its spread, and guide appropriate treatment plans. These diagnostic approaches include imaging studies, endoscopic examinations, tissue biopsies, blood tests, and advanced molecular analyses, all aimed at providing an accurate and timely diagnosis.

The gastric cancer diagnostics market growth is attributed to the increasing number of gastric cancer cases around the world, which naturally leads to a higher demand for diagnostic services. Additionally, there is a growing emphasis on early detection through screening programs, as finding the cancer early often improves treatment success. The industry is also benefiting from ongoing technological advancements, with newer, more precise, and less invasive diagnostic tools becoming available, which helps identify the disease more effectively and tailoring treatments to individual patients.

Gastric Cancer Diagnostics Market Report Highlights

By product, the reagents & consumables segment held the largest share in 2024 as reagents and consumables are essential for almost every diagnostic test, from routine blood work to advanced molecular analyses.

By disease type, the adenocarcinoma segment held the largest share in 2024, due to its overwhelming prevalence as the most common form of gastric cancer. The majority of diagnostic efforts and resource allocation are naturally directed toward identifying and characterizing this widespread disease type.

By end use, the hospitals segment held the largest share in 2024 as they are the primary healthcare facilities where patients typically receive initial diagnoses, undergo endoscopic procedures, and access comprehensive diagnostic infrastructure.

The North America gastric cancer diagnostics market accounted for the largest share in 2024, due to advanced healthcare infrastructure, high awareness regarding early diagnosis, and a strong focus on precision medicine. The market in Asia Pacific is expanding rapidly, driven by the highest global incidence of gastric cancer, particularly in East Asian countries.

A few key players in the market include F. Hoffmann-La Roche Ltd.; Abbott Laboratories; QIAGEN; Bio-Rad Laboratories, Inc.; Agilent Technologies, Inc.; Illumina, Inc.; Myriad Genetics, Inc.; Mirxes Pte. Ltd.; Vela Diagnostics; BIOMERIEUX; and AI Medical Service Inc.

Polaris Market Research has segmented the gastric cancer diagnostics market report on the basis of product, disease type, end use, and region:

By Product Outlook (Revenue - USD Billion, 2020-2034)

Reagents & Consumables

Instruments

By Disease Type Outlook (Revenue - USD Billion, 2020-2034)

Adenocarcinoma

Gastric lymphoma

Others

By End Use Outlook (Revenue - USD Billion, 2020-2034)

Hospitals

Diagnostic Laboratories

Diagnostic Imaging

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Gastric Cancer Diagnostics Market Insights

  • 4.1. Gastric Cancer Diagnostics Market - Market Snapshot
  • 4.2. Gastric Cancer Diagnostics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Global Incidence of Gastric Cancer
      • 4.2.1.2. Advancements in Diagnostic Technologies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited early detection methods
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Gastric Cancer Diagnostics Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Gastric Cancer Diagnostics Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
  • 5.3. Reagents & Consumables
    • 5.3.1. Global Gastric Cancer Diagnostics Market, by Reagents & Consumables, by Region, 2020-2034 (USD Billion)
  • 5.4. Instruments
    • 5.4.1. Global Gastric Cancer Diagnostics Market, by Instruments, by Region, 2020-2034 (USD Billion)

6. Global Gastric Cancer Diagnostics Market, by Disease Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
  • 6.3. Adenocarcinoma
    • 6.3.1. Global Gastric Cancer Diagnostics Market, by Adenocarcinoma, by Region, 2020-2034 (USD Billion)
  • 6.4. Gastric lymphoma
    • 6.4.1. Global Gastric Cancer Diagnostics Market, by Gastric lymphoma, by Region, 2020-2034 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Gastric Cancer Diagnostics Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
  • 7.4. Diagnostic Laboratories
    • 7.4.1. Global Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)
  • 7.5. Diagnostic Imaging
    • 7.5.1. Global Gastric Cancer Diagnostics Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Gastric Cancer Diagnostics Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Gastric Cancer Diagnostics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Gastric Cancer Diagnostics Market - North America
    • 8.3.1. North America: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
    • 8.3.2. North America: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.4. Gastric Cancer Diagnostics Market - U.S.
      • 8.3.4.1. U.S.: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.5. Gastric Cancer Diagnostics Market - Canada
      • 8.3.5.1. Canada: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
  • 8.4. Gastric Cancer Diagnostics Market - Europe
    • 8.4.1. Europe: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.4. Gastric Cancer Diagnostics Market - UK
      • 8.4.4.1. UK: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.5. Gastric Cancer Diagnostics Market - France
      • 8.4.5.1. France: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.6. Gastric Cancer Diagnostics Market - Germany
      • 8.4.6.1. Germany: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.7. Gastric Cancer Diagnostics Market - Italy
      • 8.4.7.1. Italy: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.8. Gastric Cancer Diagnostics Market - Spain
      • 8.4.8.1. Spain: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.9. Gastric Cancer Diagnostics Market - Netherlands
      • 8.4.9.1. Netherlands: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.10. Gastric Cancer Diagnostics Market - Russia
      • 8.4.10.1. Russia: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.11. Gastric Cancer Diagnostics Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
  • 8.5. Gastric Cancer Diagnostics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.4. Gastric Cancer Diagnostics Market - China
      • 8.5.4.1. China: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.5. Gastric Cancer Diagnostics Market - India
      • 8.5.5.1. India: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.6. Gastric Cancer Diagnostics Market - Malaysia
      • 8.5.6.1. Malaysia: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.7. Gastric Cancer Diagnostics Market - Japan
      • 8.5.7.1. Japan: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.8. Gastric Cancer Diagnostics Market - Indonesia
      • 8.5.8.1. Indonesia: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.9. Gastric Cancer Diagnostics Market - South Korea
      • 8.5.9.1. South Korea: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.10. Gastric Cancer Diagnostics Market - Australia
      • 8.5.10.1. Australia: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.11. Gastric Cancer Diagnostics Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
  • 8.6. Gastric Cancer Diagnostics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.4. Gastric Cancer Diagnostics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.5. Gastric Cancer Diagnostics Market - UAE
      • 8.6.5.1. UAE: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.6. Gastric Cancer Diagnostics Market - Israel
      • 8.6.6.1. Israel: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.7. Gastric Cancer Diagnostics Market - South Africa
      • 8.6.7.1. South Africa: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.8. Gastric Cancer Diagnostics Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
  • 8.7. Gastric Cancer Diagnostics Market - Latin America
    • 8.7.1. Latin America: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.4. Gastric Cancer Diagnostics Market - Mexico
      • 8.7.4.1. Mexico: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.5. Gastric Cancer Diagnostics Market - Brazil
      • 8.7.5.1. Brazil: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.6. Gastric Cancer Diagnostics Market - Argentina
      • 8.7.6.1. Argentina: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.7. Gastric Cancer Diagnostics Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Gastric Cancer Diagnostics Market, by Product, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Gastric Cancer Diagnostics Market, by Disease Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Gastric Cancer Diagnostics Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Agilent Technologies, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. AI Medical Service Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. BIOMERIEUX
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bio-Rad Laboratories, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. F. Hoffmann-La Roche Ltd
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Illumina, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Mirxes Pte. Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Myriad Genetics, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. QIAGEN
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Vela Diagnostics
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제